A Safety/Efficacy Study of a Non-steroid, Topical Cream Treatment of Psoriasis Over 12-weeks

NCT01098721 | Completed Phase 2 DMC

• 2 other identifiers: WBI-1001-102134993
• Study Type: interventional
• Target: 61
• Locations: 0 countries
• Sites: N/A

Brief Summary

Psoriasis is a chronic inflammatory skin disorder that is characterized by hyperproliferation of the keratinocytes and inflammation of the epidermal and dermal layers of the skin. This study, in patients with mild to moderate plaque psoriasis, is designed to further determine the efficacy, safety and tolerability of the novel, topically applied, non-steroid, anti-inflammatory WBI-1001 cream over a period of 12 weeks.

Conditions

Psoriasis

Keywords

plaque psoriasis; skin diseases; anti-inflammatory; non-steroid; topical cream

Outcome Measures

Primary Outcomes (1)

• Change from baseline (Day 0) in PGA in patients randomized to placebo as compared to patients randomized to 1.0% WBI-1001.

  The primary indication of efficacy will be demonstrated by improvement in the Physician's Global Assessment (PGA) in patients treated with the active (1.0% WBI-1001) cream as compared with those treated with the placebo cream.

  84 days

Secondary Outcomes (8)

• Change in PASI score from baseline (Day 0) to Day 84 for patients in Group 1 compared with those in Group 2.

  84 days

• Blood and urine analyses and vital signs assessments of patients from Day 0 to Day 84, and the follow-up at Day 112.

  84 days plus 112 day follow-up.

• Change from baseline in BSA at Day 84 in patients randomized to placebo compared with those randomized to 1.0% WBI-1001 cream treatment.

  84 days

• Change from baseline (Day 0) in mean target lesion score at Day 84 in patients in Group 1 compared with those in Group 2.

  84 days

• Change from baseline (Day 0)in target lesion induration at Day 84 in patients in Group 1 compared with those in Group 2.

  84 days

Study Arms (2)

Group 1

PLACEBO COMPARATOR

A placebo cream applied topically twice daily (BID)by each of 20 patients, once in the morning and once in the evening for 12 weeks.

Drug: WBI-1001

Group 2

ACTIVE COMPARATOR

A 1.0% WBI-1001 cream applied topically twice daily (BID) by each of 40 patients, once in the morning and once in the evening for 12 weeks.

Drug: WBI-1001

Interventions

WBI-1001 DRUG

Comparison of two doses (0% and 1.0%) of the the WBI-1001 cream applied topically, twice daily for 12 weeks.

Group 1; Group 2

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• A clinical diagnosis of stable plaque psoriasis for at least 6 months representing a maximum of 10% of BSA with a minimum of 1% BSA excluding the face, groin ,scalp and genital regions and with a minimum of one target plaque that is at least 2 x 2 cm in size at Day 0.
• PGA of 2 to 4 at Day 0.
• In good general health and free of any disease state or physical condition that might impair the evaluation of plaque psoriasis.
• Women of child bearing potential (WOCBP) must have a negative serum beta-human chorionic gonadotrophin (b-hCG) pregnancy test before randomization. WOBCP who are not abstinent from sex with male partners may be entered into the study if they are willing to continue to use adequate contraceptive precautions for the duration of the study. Male patients with female sexual partners who are able to become pregnant must ensure that an acceptable method of birth control is used while they are in the study. Women who are lactating will not be eligible for the study.
• Willing and able to comply with the protocol and likely to attend all study visits.
• Provide written, informed consent prior to the initiation of any study-related procedures.

You may not qualify if:

• Spontaneously improving or rapidly deteriorating plaque psoriasis.
• Any other skin diseases that might interfere with the clinical assessment of plaque psoriasis and/or put the patient at risk.
• Pustular, erythrodermic or other non-plaque forms pf psoriasis.
• Guttate psoriasis as the dominant form of psoriasis.
• Other concomitant, serious illness or medical condition (eg., human immunodeficiency virus, renal insufficiency, clinically significant abnormal laboratory values) that could put the patient at risk during the study.
• History of neurological/psychiatric disorders, including psychotic disorders or dementia, or any other reason that would interfere with the patient's participation in the trial.
• Systemic immunomodulatory therapy known to affect psoriasis and decreases immune cell populations (eg., alefacept) within 24 weeks of the baseline visit.
• Systemic immunomodulatory therapy known to affect psoriasis and that does not typically decrease immune cell populations (eg., etanercept) within 12 weeks prior to the baseline visit.
• Any phototherapy (including laser for the treatment of psoriasis), photo-chemotherapy,or systemic psoriasis therapy (such as systemic corticosteroids, methotrexate, retinoids or cyclosporine) within 4 weeks prior to the baseline visit.
• Prolonged exposure to artificial or natural sources of ultraviolet radiation within 4 weeks prior to the baseline visit or intention to have such exposure during the study, thought by the investigator likely to modify the patient's psoriasis.
• Topical anti-psoriatic therapy (including topical retinoids and vitamin D analogs) on the areas to be treated within 2 weeks prior to the baseline visit.
• Alcohol abuse during the last 2 years as defined by the consumption of \>14 standard drinks of alcohol per week.
• Use of lithium within 2 weeks prior to the screening visit.
• Use of beta blockers (eg., propranolol) within 2 weeks prior to the screening visit unless on a stable dose for \>3 months.
• Known or suspected hypersensitivity to any of the constituents of the investigational product.

Sponsors & Collaborators

• Welichem Biotech Inc.: lead

MeSH Terms

Conditions

Psoriasis; Skin Diseases

Interventions

tapinarof

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin and Connective Tissue Diseases

Study Officials

• Robert Bissonnette, MD, MSc

  Innovaderm Research Inc.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 1, 2010
• First Posted: April 5, 2010
• Study Start: January 1, 2010
• Primary Completion: September 1, 2010
• Study Completion: November 1, 2010
• Last Updated: December 20, 2012

Record last verified: 2012-12